drugset / Trial / NCT04681677

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

NCT04681677 ↗

Phase 2 Terminated 12 enrolled Xoft, Inc. Icad, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be made to the results of the EBRT + Bevacizumab arm of RTOG 1205.

Timeline

Start
2021-11-02
Primary completion
2024-04-24
Completion
2024-04-24

Outcome

Outcome not reported

Stopped (Business): “unspecified business decision”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —

Indications